Impact of highly conserved HLA haplotype on acute graft-versus-host disease (original) (raw)
Related papers
Experimental and Clinical Transplantation, 2020
HLA-E is located on the nonclassical major histocompatibility complex class I and acts as the ligand for natural killer cells. Consequently, it has a main role in the regulation of innate immune responses by involving cell identification by natural killer cells. Differences in expression levels among HLA-E alleles have been suggested to affect transplant outcomes. In this study, we evaluated the effects of different HLA-E genotypes on allogeneic hema-topoietic stem cell transplant in southern Iran. Materials and Methods: We investigated 200 patients (donors and recipients) who underwent allogeneic hematopoietic stem-cell transplant and 100 normal participants (control group) in a case-control study. Detection of HLA-E polymorphisms was performed using a sequence-specific primer polymerase chain reaction method. Results: Statistical analyses indicated that genotypes in the transplant group were not distributed in accordance with Hardy-Weinberg equilibrium (χ 2 = 76.56; P < .001), whereas genotypes in the control group were distributed in accordance with Hardy-Weinberg equilibrium (χ 2 = 0.39; P = .53). No significant differences were observed in cumulative incidence of acute (P = .76; hazard ratio = 0.80; 95% confidence interval, 0.19-3.31) and chronic (P = .75, hazard ratio = 0.048; 95% confidence interval, 0.00) graft-versus-host disease in recipients harboring HLA-E*0103 allele compared with those homozygous for the HLA-E*0101 allele. The HLA-E*0103 allele showed a trend toward lower cumulative incidence of relapse compared with the homozygous HLA-E*0101 genotype (8% vs 21.5%; P = .37; hazard ratio = 2.50; 95% confidence interval, 0.32-19.20).
Biological significance of HLA locus matching in unrelated donor bone marrow transplantation
Blood, 2015
We hypothesized that the compatibility of each HLA loci between donor and patient induced divergent transplant-related immunologic responses, which attributed to the individualized manifestation of clinical outcomes. Here, we analyzed 7898 Japanese pairs transplanted with T-cell-replete marrow from an unrelated donor with complete HLA allele typing data. Multivariable competing risk regression analyses were conducted to evaluate the relative risk (RR) of clinical outcomes after transplantation. A significant RR of HLA allele mismatch compared with match was seen with HLA-A, -B, -C, and -DPB1 for grade III-IV acute graft-versus-host disease (GVHD), and HLA-C for chronic GVHD. Of note, only HLA-C and HLA-DPB1 mismatch reduced leukemia relapse, and this graft-versus-leukemia effect of HLA-DPB1 was independent of chronic GVHD. HLA-DRB1 and HLA-DQB1 double (DRB1_DQB1) mismatch was revealed to be a significant RR for acute GVHD and mortality, whereas single mismatch was not. Thus, the num...
Biologia, 2020
Graft-versus-host disease (GVHD) in its acute (aGVHD) and chronic (cGVHD) form remains one of the most serious complications of allogeneic haematopoietic stem cell transplantation (allo-HSCT). There are several risk factors known to be associated with GVHD development. Some reports suggest that certain human leukocyte antigen (HLA) variants may influence the incidence of GVHD. The aim of our study was to analyse possible association between individual HLA alleles and the occurrence of aGVHD and cGVHD in patients following allo-HSCT from HLA-identical sibling donors. We have retrospectively reviewed medical records of 96 patients who received a transplant in the years 1994-2008. Cumulative incidence of acute GVHD was 31.3% and that of chronic GVHD was 26.0%. Recipients carrying the HLA-A*01,-DRB1*03 and-DQB1*03 alleles showed a statistically significantly lower incidence of aGVHD. Furthermore, the HLA-DQB1*06 allele was associated with a higher incidence of cGVHD. Each of these alleles was confirmed by logistic regression analysis as an independent factor with impact on GVHD development. Our results support findings of authors showing an association between certain HLA variants and GVHD appearance. However, other authors assume that there is no convincing evidence for such an association. Therefore, when taking into account limitations of our study design and the significant inconsistency in the results of the previous reports, a careful approach in judgement is required. To conclude, in our view, the prognostic value of individual HLA variants for GVHD development in a setting of HLA-identical allo-HSCT does not seem to be of great clinical relevance. Keywords Haematopoietic stem cell transplantation. Human leukocyte antigens. Graft-versus-host disease Abbreviations aGVHD Acute graft-versus-host disease allo-HSCT Allogeneic haematopoietic stem cell transplantation cGVHD Chronic graft-versus-host disease CI Confidence interval CsA Cyclosporin A HLA Human leukocyte antigens HSCT Haematopoietic stem cell transplantation miHA Minor histocompatibility antigens MTX Methotrexate
Haematologica, 2016
HLA molecules play an important role for immunoreactivity in allogeneic hematopoietic stem cell transplantation. To elucidate the effect of specific HLA alleles on acute graft-versus-host disease, we conducted a retrospective analysis using 6967 Japanese patients transplanted with T-cell-replete marrow from an unrelated donor. Using unbiased searches of patient and donor HLA alleles, patient and/or donor HLA-B*51:01 (patient: HR, 137; P<0.001, donor: HR, 1.35; P<0.001) and patient HLA-C*14:02 (HR, 1.35; P<0.001) were significantly associated with an increased risk of severe acute graft-versus-host disease. The finding that donor HLA-C*14:02 was not associated with severe acute graft-versus-host disease prompted us to elucidate the relation of these high risk HLA alleles with patient and donor HLA-C allele mismatches. In comparison to HLA-C allele match, patient mismatched HLA-C*14:02 showed the highest risk of severe acute graft-versus-host disease (HR, 3.61; P<0.001) an...
Frontiers in Immunology, 2011
Background: Human leukocyte antigen-G (HLA-G) molecules play a prominent role in immune tolerance. Structurally similar to their classical HLA homologs, they are distinct by having high rate of polymorphism in the non-coding regions including a functionally relevant 14-base pair (bp) insertion/deletion (Ins/Del) allele in the 3 untranslated region (3 UTR), rarely examined in a hematopoietic stem cell transplantation (HSCT) setting. Here, we analyzed the potential impact of HLA-G Ins/Del dimorphism on the incidence of acute graft-versus-host disease (aGvHD), transplant-related mortality (TRM), overall survival (OS), and incidence of relapse after HSCT using bone marrow (BM) as stem cell source from HLA-matched donors. Methods: One hundred fifty-seven sibling pairs, who had undergone HSCT, were studied for the distribution of the HLA-G 14 bp Ins/Del polymorphism using a polymerase chain reaction (PCR)-based technique. Potential genetic association with the incidence of aGvHD, TRM, and OS was analyzed by monovariate and multivariate analyses. Results: Monovariate analysis showed that the homozygous state for the 14-bp Ins allele is a risk factor for severe aGvHD (grade III and IV; P = 0.008), confirmed subsequently by multivariate analysis [hazard ratio (HR) = 3.5; 95% confidence interval (95%CI) = 1.3-9.5; P = 0.012]. We did not find any association between HLA-G polymorphism and the other studied complications. Conclusion: Our data suggest that the HLA-G low expressor 14 bp Ins allele constitutes a risk factor for the incidence of severe aGvHD in patients who received BM as stem cell source.
Transplantation, 2009
Background. Hematopoietic stem-cell transplantation is a well-established treatment in various hematologic malignancies, but the outcome depends on disease relapse, infections, and the development and severity of acute and chronic graft-versus-host disease. Some evidence has revealed an important role for the nonclassical major histocompatibility complex class I molecules in transplantation, most notably human leukocyte antigen (HLA)-E. This study evaluates the impact of HLA-E alleles on transplantation outcome after HLA-matched allogeneic HSCT. Methods. We genotyped DNA for HLA-E polymorphism from 83 recipients and their respective donors by real-time polymerase chain reaction after melting curve analysis and compared the results with clinical outcome. Results. HLA-E*0103 homozygous patients showed a higher probability of overall survival (Pϭ0.003) and disease-free survival (Pϭ0.001) in a univariate model. Cox regression analysis confirmed HLA-E*0103, 0103 (Pϭ0.006; relative risk 1.12; 95% confidence interval 0.31-1.94) and early stage of disease (Pϭ0.005; relative risk 1.16; 95% confidence interval 0.45-1.86) as independent factors improving overall survival. Moreover, homozygosity for HLA-E*0103 was associated with a significant decreased incidence of transplant-related mortality (Pϭ0.01). Conclusions. We found an association between HLA-E*0103 homozygosity and the significant reduction of transplant-related mortality in related and unrelated HSCT. The risk of posttransplant complications was significantly reduced when the donor possesses the HLA-E*0103, 0103 genotype, and this was translated in a better overall survival.